Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218231 · ClinicalTrials.gov registry record · Phase 2
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00218231 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 48 participants.
The verdict
NCT00218231, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.
Interventions
- DRUG 300 mg/day bupropion-sr
- DRUG 0 mg/day bupropion-sr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218231
The ClinicalTrials.gov registry entry for NCT00218231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 300 mg/day bupropion-sr is the first listed.
NCT00218231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218231 about?
NCT00218231 is a clinical study titled "Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia". Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.
What is the current status of trial NCT00218231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2004-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00218231?
The interventions under investigation include: 300 mg/day bupropion-sr (DRUG), 0 mg/day bupropion-sr (DRUG).
Who is sponsoring clinical trial NCT00218231?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.